A New Jersey pilates instructor who was once given a “dismal” prognosis following a recurring bout of aggressive lymphatic cancer is now in complete remission, thanks to a high-tech form of immunotherapy known as CAR-T cell therapy.
Debi Weiss, 72, is back to her daily routine of teaching and walking her dog, months after doctors discovered her cancer had spread to her brain. Her recovery highlights the life-saving potential of genetically engineered “living drugs” in treating late-stage lymphomas that fail to respond to traditional chemotherapy.
The Hidden Danger: From Flu Symptoms to DLBCL
The medical odyssey began when Weiss experienced what she initially dismissed as a standard case of the flu. However, as her condition deteriorated—leaving her unable to breathe properly or perform basic physical tasks—diagnostic blood tests and a biopsy revealed a far more sinister reality: diffuse large B-cell lymphoma (DLBCL).
According to the Mayo Clinic, DLBCL is an aggressive, fast-growing cancer of the lymphatic system. For Weiss, the diagnosis was a profound shock. “It was very much an out-of-body experience,” she told CBS News.
While Weiss immediately underwent standard chemotherapy, the reprieve was short-lived. Just one month after completing her initial treatment, follow-up scans revealed the lymphoma had not only recurred but had metastasized to her brain.
:max_bytes(150000):strip_icc():focal(732x0:734x2):format(webp)/debie-weiss-doctors-031326-5d9bad0e5a54484e8f7a2c1ab22f5830.jpg)
A “Dismal” Outlook and the CAR-T Turning Point
The recurrence presented a critical challenge for her medical team at Atlantic Health Morristown Medical Center. Dr. Charles Farber, a hematologist-oncologist, noted that her prognosis at that stage appeared “dismal.”
Faced with failing conventional treatments, Weiss’s physicians turned to CAR-T (Chimeric Antigen Receptor T-cell) therapy in January 2025.
How CAR-T Therapy Works
Dr. Mohamad Cherry, Medical Director of Hematology at Atlantic Health, describes the process as a sophisticated biological intervention:
- Extraction: A patient’s T-cells (immune cells) are removed from their blood.
- Genetic Engineering: The cells are modified in a laboratory to recognize and attack specific cancer cell proteins.
- Reinfusion: The “supercharged” cells are infused back into the patient, functioning like a targeted, internal search-and-destroy mission.
Weiss famously visualized the treatment through a “Pac-Man” analogy, inspired by drawings a nurse placed on her hospital whiteboard. “They were going to come into my body and Pac-Man themselves all the way around, and eat up all my cancer cells,” Weiss recalled.
:max_bytes(150000):strip_icc():focal(665x0:667x2):format(webp)/debie-weiss-welcomeback031326-ef18db02cbe046ec8b4cfe7c07e9f858.jpg)
A New Lease on Life
The results were transformative. Weiss reported no significant side effects from the procedure—a common concern with intensive immunotherapy—and quickly regained her mobility.
Dr. Farber confirmed that Weiss is currently in complete remission. While she will continue to undergo rigorous monitoring with scans every four to six months, her clinical recovery is being hailed as a success for advanced immunotherapy.
For Weiss, the survival has brought a shift in perspective typical of those who have faced terminal diagnoses. She has recalibrated her priorities, placing family and personal boundaries above her professional schedule.
“Life is better than it was before in a lot of ways,” Weiss said. “I don’t have time to spend with people that I really don’t want to spend time with. I’m honest enough with myself to say ‘no.’ It’s been a great year.”
